Immune drug tested to halt diabetes progression
NCT ID NCT05574335
Summary
This early-stage study tested different doses of an immune therapy called siplizumab in people recently diagnosed with type 1 diabetes. The main goal was to find a safe dose that changes certain immune cells, which might help protect the body's remaining insulin-producing cells. Researchers also checked if the treatment helped preserve the body's own insulin production and monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Benaroya Research Institute at Virginia Mason: Diabetes Research Program
Seattle, Washington, 98101, United States
-
Columbia University Medical Center: Naomi Berrie Diabetes Center
New York, New York, 10032, United States
-
University of Colorado School of Medicine: Barbara Davis Center for Diabetes
Aurora, Colorado, 80045, United States
-
University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
Iowa City, Iowa, 52242, United States
-
University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.